Giuseppe Saglio Haruo Sugiyama Eckhard Thiel · 4 08.30 Welcome address 08.45 Giuseppe Saglio, Haruo Sugiyama, Eckhard Thiel 08.45 SESSION 1 - Physiology and pathophysiology of WT1

1

INTERNATIONAL CONFERENCE ON 5TH

WT1 IN HUMAN NEOPLASIA

Presidents:

Giuseppe Saglio Haruo Sugiyama

Eckhard Thiel

Torino, April 15 - 16, 2011 Congress Center Torino Incontra

REQUESTED AUSPICES:EHA European Hematology Association

SIE Italian Society of Hematology

SIES Italian Society of Experimental Hematology

3

FACULTY

Elizabeth M. Algar Melbourne - Australia

Sébastien Anguille Edegem - Belgium

Daphné Benteyn Bruxelles - Belgium

Zwi N. Berneman Edegem - Belgium

Anna Candoni Udine - Italy

Daniela Cilloni Torino - Italy

Vito Michele Fazio Roma - Italy

Jude Fitzgibbon London - United Kindom

Hiroshi Fujiwara Toon - Japan

John Goldman London - United Kindom

David Grimwade London - United Kindom

Naoya Hashimoto Osaka - Japan

Yuji Heike Tokyo - Japan

Naoki Hosen Osaka - Japan

Vicki Huff Houston - USA

Joop H. Jansen Nijimegen - the Netherlands

Ulrich Keilholz Berlin - Germany

Francesco Lo Coco Roma - Italy

Karim Malik Bristol - United Kindom

Sumiyuki Nishida Osaka - Japan

Josep Nomdedéu Barcelona - Spain

Yusuke Oji Osaka - Japan

Yoshihiro Oka Osaka - Japan

Fabrizio Pane Napoli - Italy

Katayoun Rezvani London - United Kindom

Giuseppe Saglio Torino - Italy

Egawa Shinichi Osaka - Japan

Haruo Sugiyama Osaka - Japan

Eckhard Thiel Berlin - Germany

Akihiro Tsuboi Osaka - Japan

Viggo Van Tendeloo Antwerp - Belgium

Nicole Wagner Paris - France

Bettina Wilm Bristol - United Kindom

4

08.30 Welcome address 08.45 Giuseppe Saglio, Haruo Sugiyama, Eckhard Thiel

08.45 SESSION 1 - Physiology and pathophysiology of WT110.45 Chairmen: Elizabeth M. Algar, Fabrizio Pane

• WT1 and epigenetic regulation Karim Malik

• Germline and somatic mutations of WT1 in human disease Elizabeth M. Algar

• Oral Communication to be defined according to the abstract selection

• Oral Communication speaker to be defined according

• Oral Communication speaker to be defined according 10.45 Coffee break11.15 11.15 SESSION 2 - WT1 Immunology and Preclinical Studies13.00 Chairmen: Vito Michele Fazio, Giuseppe Saglio

• Modification of a WT1 - encoding plasmid to enhance translational efficacy and t cell stimultatory capacity of WT1 mrna - electroporated dendritic cells

Daphné Benteyn, Sébastien Anguille

• Oral Communication to be defined according to the abstract selection

• Oral Communication to be defined according to the abstract selection

• Oral Communication speaker to be defined according to the abstract selection

13.00 Lunch14.00

Friday, April 15, 2011

5

14.00 SESSION 3 - WT1: methodological aspects (RQ-PCR, 15.30 protein detection, mutational analysis) Chairmen: Yuji Heike, Joop H. Jansen

• Regulation of WT1 by microRNAs Joop H. Jansen

• Protein detection Yuji Haike, Joop H. Jansen

• Standardization of WT1 immunohistochemical staining and evaluation of WT1 positivity in solid cancers

Yusuke Oji

• WT1 in angiogenesis Nicole Wagner

15.30 Coffee break16.00

16.00 SESSION 4 - WT1 as prognostic marker 17.15 Chairmen: Daniela Cilloni, Josep Nomdedéu

• MRD detection in AML using WT1: the Catalan experience Josep Nomdedéu

• Prognostic significance of WT1 mutations in AML Daniela Cilloni

• WT1 detection post bone marrow transplantation: prognostic significance

Anna Candoni

17.15 SESSION 5 - WT1 as marker for MRD detection 18.00 Chairmen: David Grimwade, Yusuke Oji

• Development of optimised RQ-PCR assays for detection of WT1 transcripts to predict outcome in AML

David Grimwade

• Peripheral blood or bone marrow for MRD detection? Daniela Cilloni

20.00 Social Dinner

MEETING AGENDA

6

08.30 SESSION 6 – Immunotherapy I: 09.45 Clinical trials in hematological malignancies Chairmen: Zwi N. Berneman, Katayoun Rezvani • Induction of complete and molecular remissions in acute

myeloid leukemia by WT1-targeted dendritic cell vaccination Zwi N. Berneman

• WT1 vaccination trial in CML Katayoun Rezvani

• Reduced dose of WT1 vaccine for myelodysplastic syndrome – phase I clinical study

Akihiro Tsuboi

09.45 SESSION 7 – Immunotherapy II: 11.00 Clinical trials in hematological malignancies Chairmen: Yoshihiro Oka, Haruo Sugiyama • Title to be defined Jude Fitzgibbon

• A different target for immunotherapy in hematological tumors: the Prame antigens

Fabrizio Pane

• WT1 peptide vaccination therapy against hematological malignancies post stem cell transplant

Naoki Hosen

• Long-term WT1 peptide vaccination for the patients with acute myeloid leukemia

Akihiro Tsuboi

11.00 Coffee break 11.30

11.30 SESSION 8 – Immunotherapy III: 13.00 Clinical trials in solid tumors Chairmen: Ulrich Keilholz, Hiroshi Fujiwara • Results of the 18 published trials of WT1-directed vaccination

in hematological malignancies and solid tumors Viggo Van Tendeloo

• Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene

Vicki Huff

Saturday, April 16, 2011

7

• WT1 peptide-based cancer vaccine in combination with gemcitabine in patients with advanced pancreatic cancer - phase I clinical trial

Sumiyuki Nishida

• WT1 immunotherapy for malignant glioma: recursive partitioning analyses and prognostic factors

Naoya Hashimoto

• Pilot trial of Wilms Tumor 1 (WT1) peptide vaccine therapy for chemorefractory advanced pancreatic cancer

Egawa Shinichi

13.00 Lunch14.00

14.00 SESSION 9 – Immunotherapy: Future perspectives15.30 Chairmen: John Goldman, Francesco Lo Coco

• Which kind of immunotherapy to defeat LSCs? John Goldman

• Curing leukemias: the model of APL Francesco Lo Coco

• A report of the first international WT1 meeting, University of Manchester UK, 2008

Bettina Wilm

• Oral Communication speaker to be defined according to the asbtract selection

15.30 Summary and concluding remarks16.00 Haruo Sugiyama, Eckhard Thiel

16.00 Meeting end

8

PRESENTATION GUIDELINES

Presentation Time12 min for presentation and 3 min for Q&A are given to each presentation.

Preparation of Presentation MaterialsAll speakers must use electronic files (in PowerPointTM in Win) to present at the conference. Powerpoint 2007 is available on the prepared PC. Please prepare your files in PowerPoint and check whether your file is compatible to Win PC. All the speakers must bring their presentation files in their media (USB flash-memory or CD-ROM) to the slide center.

CALL FOR ABSTRACT FOR POSTER SESSION Abstract should be submitted by March 15, 2011 by email to the Scientific Secretariat: [email protected]

Topics:• Physiology and pathophysiology of WT1• WT1 Immunology and Preclinical Studies• WT1: methodological aspects (RQ-PCR, protein detection, mutational

analysis)• WT1 as Prognostic marker• WT1 as marker for MRD detection• Immunotherapy I: Clinical trials in hematological malignancies • Immunotherapy II: Clinical trials in solid tumors• Immunotherapy: Future perspectives

Abstract should undergo the following parameters:• Language: English • Title in capital letters • Authors: Surname and name • Affiliations • Main text: body 12, max 5.000 types (included space), max 3 relevant

tables and/or figures (in total) • References: max 5 references allowed • Full details about a corresponding author to whom send all requests

must be provided

ITALIAN CMEApplication for Italian CME credits has been made for physicians and biologists.

EUROPEAN CME Application for European CME credits has been made for physicians and biologists.

SCIENTIFIC INFORMATION

9

MEETING VENUECongress Center Torino IncontraVia Nino Costa 8 - 10123 Torino - ItalyPh. +39 011 5576800 Fax +39 011 5576809 www.torinoincontra.org

HOW TO REACH THE MEETING VENUEBy car: Highway access: A5 Torino-Ivrea-Aosta (Alps tunnels Gran San Bernardo,

Mont Blanc) A6 Savona-Ligurian Riviera A21 Piacenza-Bologna-Firenze A32 Torino-Bardonecchia-Frejus Near the meeting venue there is a big car parking called

“Piazzale Valdo Fusi”.

By plane: the international airport “Torino Caselle” is 15 Km far from the Congress Center.

By train: there are two railway stations: Torino Porta Nuova: 1 Km far from the Congress Center. Torino Porta Susa: 2,2 Km far from the Congress Center.

OFFICIAL LANGUAGEEnglish.

BADGEAll registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATEA certificate will be given to all participants at the end of the Meeting.

REGISTRATION

The registration is free. Please fill in the registration form here enclosed and send back to the Organizing Secretariat by April 1, 2011:

Studio E.R. Congressi – Triumph GroupVia Marconi, 36 – 40122 Bologna - ItalyPh. +39 051 4210559 Fax +39 051 [email protected] www.ercongressi.it

GENERAL INFORMATION

10

SOCIAL DINNERFee Euro 100,00 (Italian VAT included)

The social dinner wil be held:Friday, April 15, 2011 at 20.00

Museo del CinemaVia Montebello, 22 – Torino

Before the buffet dinner there will be a guided tour of the Museum. The Museum is situated near the Congress Center Torino Incontra (15 minutes by foot).We will accept reservation for the Social Dinner only before April 1, 2011.

HOTEL BOOKING AND TRAVEL AGENCYParticipants are kindly requested to contact the Hotel Booking Agency, Bononia Viaggi, in order to arrange their accomodation in Italy by April 1, 2011.

Bononia Viaggi Piazza dei Martiri, 1 - 40121 Bologna - Italy Ph. +39 051 4211585Fax +39 051 249846 [email protected]

CHANGESParts of the program may be changed if necessary without notice.

11

12

Organizing Secretariat:

Studio E.R. Congressi – Triumph Group

Via Marconi, 36 – 40122 Bologna - ItalyPh. +39 051 4210559 Fax +39 051 [email protected] www.ercongressi.it

Scientific Secretariat:

Daniela Cilloni

Ospedale S. Luigi Regione Gonzole, 10

10043 Orbassano – Italy Ph. +39 011 6705475

[email protected]